Wockhardt Ltd. - Research Center
532300 WOCKPHARMA Group (T) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Sales | 1,072.00 | 1,372.00 | 987.26 | 890.06 | 2,149.95 |
| Operating profit | 70.00 | 222.00 | -137.70 | -133.14 | 86.11 |
| Interest | 229.00 | 273.00 | 200.24 | 220.17 | 170.63 |
| Gross profit | -92.00 | -13.00 | -297.21 | -310.29 | -53.52 |
| EPS (Rs) | -32.36 | -9.72 | 53.56 | -20.87 | -7.40 |
Annual
results in details
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Other income | 67.00 | 38.00 | 40.73 | 43.02 | 31.00 |
| Stock adjustment | 30.00 | 2.00 | -1.78 | -8.61 | 5.03 |
| Raw material | 200.00 | 283.00 | 253.10 | 236.70 | 464.73 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 240.00 | 261.00 | 293.36 | 325.46 | 482.20 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 532.00 | 604.00 | 580.28 | 469.65 | 1,111.88 |
| Provisions made | - | - | - | - | - |
| Depreciation | 186.00 | 171.00 | 184.08 | 173.39 | 121.91 |
| Taxation | -47.00 | -44.00 | -231.73 | -158.00 | -93.54 |
| Net profit / loss | -466.00 | -140.00 | 593.29 | -231.12 | -81.89 |
| Extra ordinary item | -235.00 | - | 842.85 | 94.56 | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 72.00 | 72.00 | 55.39 | 55.37 | 55.34 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 6.53 | 16.18 | -13.95 | -14.96 | 4.01 |
| GPM (%) | -8.08 | -.92 | -28.91 | -33.25 | -2.45 |
| NPM (%) | -40.91 | -9.93 | 57.71 | -24.77 | -3.75 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis